At CONNECTA, we are leveraging our small-molecule neuroplasticity modulation platform with a focus on paediatric neurodevelopmental conditions. Neuroplasticity is the ability of the nervous system to adapt its activity in response to intrinsic or extrinsic stimuli by reorganizing its structure, functions, and connections, and is impaired in the vast majority of these disorders.

Unlike existing symptomatic treatments, our lead program, CTH120, is a potential first-in-class disease-modifying treatment for Fragile X syndrome (FXS), a rare and currently untreatable neurodevelopmental disorder that strongly impairs cognition and behaviour.

Backed by strong preclinical research, Phase I safety data (NCT06480968) and the assessment of neural biomarkers in FXS (NCT06957054), CONNECTA has initiated a Phase IIa trial of CTH120 currently recruiting adult males with FXS (NCT07654114), and is advancing the program into the paediatric FXS population, supported by the FRAXCURE project (co-funded by the European Innovation Council and the European Union, GA101217931).

Our scalable platform has also generated a pipeline of promising programs with demonstrated preclinical efficacy in FXS and Rett Syndrome, and potential applications in Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD), and rare Neurodevelopmental Disorders (NDDs).

CONNECTA’s shareholders include Inveready, CDTI Innvierte, Clave Capital and Prous Institute for Biomedical Research.